WG
INO icon

Winton Group’s Inovio Pharmaceuticals INO Stock Holding History

Winton Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,189
Closed -$41.2K – 932
2023
Q1 		$41.2K Sell
4,189
-255
-6% -$4.35K ﹤0.01% 935
2022
Q4 		$83.2K Buy
4,444
+300
+7% +$6.8K 0.01% 887
2022
Q3 		$86K Sell
4,144
-382
-8% -$9.78K 0.01% 899
2022
Q2 		$94K Buy
4,526
+1,096
+32% +$30.9K 0.01% 923
2022
Q1 		$148K Buy
3,430
+799
+30% +$36K 0.01% 924
2021
Q4 		$158K Buy
2,631
+294
+13% +$23.6K 0.01% 955
2021
Q3 		$201K Buy
2,337
+297
+15% +$29.8K 0.01% 1242
2021
Q2 		$227K Buy
2,040
+436
+27% +$41.9K 0.01% 1299
2021
Q1 		$179K Buy
1,604
+43
+3% +$5.66K 0.01% 1298
2020
Q4 		$166K Sell
1,561
-2,184
-58% -$291K 0.01% 1217
2020
Q3 		$521K Sell
3,745
-11,214
-75% -$2.34M 0.02% 1101
2020
Q2 		$4.84M Buy
+14,959
New +$2.4M 0.12% 222

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Winton Group's INO Position: Q2 2023 in Review

Winton Group sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 4,189 shares — an estimated $41.2K sold.

Winton Group first reported a position in INO in Q2 2020 and held it in 12 quarters. The position peaked at $4.84M in Q2 2020. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

  • Winton Group reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Winton Group sold 4,189 Inovio Pharmaceuticals shares in Q2 2023, an estimated $41.2K.
  • Winton Group first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 12 quarters.
  • Winton Group's Inovio Pharmaceuticals position peaked at $4.84M in Q2 2020.
  • 133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.